Candiforce Capsule belongs to a group of medicines called antifungals. It works by stopping the growth of fungus and is used to treat infections of the mouth, throat, vagina and other parts of the body including fingernails and toenails. It kills fungi by destroying the fungal cell membrane. It consists of itraconazole which belongs to the class of triazole derivatives. Used in the systemic treatment of mycotic infections.
Candiforce is a product from Mankind Pharma. Mankind came into existence in 1986 and became a fully-integrated pharma company in 1995. It is one of the leading Indian pharma companies with over 14000 employees and presence in 34 countries and it strive to provide world-class medications at affordable prices.
Specific Advantage – Stability over wide range of temperature and humidity, No cross linking with excipients thus enhanced dissolution
Candidiasis is a fungal infection caused by a yeast (a type of fungus) called Candida. Some species of Candida can cause infection in people; the most common is Candida albicans. Candida normally lives on the skin and inside the body, in places such as the mouth, throat, gut, and vagina, without causing any problems. Candida can cause infections if it grows out of control or if it enters deep into the body (for example, the bloodstream or internal organs like the kidney, heart, or brain). Some types of Candida are resistant to the antifungals used to treat them.
Candidiasis that develops in the mouth or throat is called thrush or oropharyngeal candidiasis. Candidiasis in the vagina is commonly referred to as a yeast infection. Invasive candidiasis occurs when Candida species enter the bloodstream or affect internal organs like the kidney, heart, or brain.
Ringworm also known as dermatophytosis, dermatophyte infection, or tinea, is a fungal infection of the skin.
Ringworm infection can affect both humans and animals. The infection initially appears as red patches on affected areas of the skin and later may spread to other parts of the body. It may affect the scalp, feet, nails, groin, beard, or other areas.
Different types of fungi cause ringworm. Doctors call ringworm different names depending on where it affects the body:
Ringworm of the scalp (tinea capitis) often starts as isolated scaling in the scalp that develops into itchy, scaly bald patches. It’s most common among children.
Ringworm of the body (tinea corporis) often appears as patches with the characteristic round ring shape.
Jock itch (tinea cruris) refers to ringworm infection of the skin around the groin, inner thighs, and buttocks. It’s most common in men and adolescent boys.
Athlete’s foot (tinea pedis) is the common name for ringworm infection of the foot. It’s frequently seen in people who go barefoot in public places where the infection can spread, such as locker rooms, showers, and swimming pools.
As directed by your Physician
As directed by your Physician
Significant: Heart failure, pulmonary oedema, neuropathy, transient or permanent hearing loss, transient asymptomatic decrease of LVEF, hepatotoxicity, hypersensitivity reactions. Blood and lymphatic system disorders: Granulocytopenia, leukopenia, thrombocytopenia. Cardiac disorders: Chest pain, tachycardia. Ear and labyrinth disorders: Tinnitus. Eye disorders: Visual disturbance, blurred vision, diplopia. Gastrointestinal disorders: Nausea, abdominal pain, vomiting, diarrhoea, dyspepsia, constipation. General disorders and administration site conditions: Oedema, fatigue, pyrexia. Hepatobiliary disorders: Jaundice, hepatitis, hyperbilirubinaemia. Immune system disorders: Urticaria. Investigations: Elevated liver enzymes, increased serum creatine phosphokinase. Metabolism and nutrition disorders: Hypokalaemia, hypertriglyceridaemia. Musculoskeletal and connective tissue disorders: Myalgia, arthralgia. Nervous system disorders: Headache, dizziness, paraesthesia, dysgeusia. Renal and urinary disorders: Pollakiuria, urinary incontinence. Reproductive system and breast disorders: Menstrual disorder, erectile dysfunction. Respiratory, thoracic and mediastinal disorders: Dyspnoea, cough, sinusitis, rhinitis. Skin and subcutaneous tissue disorders: Rash, pruritus, photosensitivity, alopecia. Vascular disorders: Hypertension, hypotension. Potentially Fatal: Rarely, acute liver failure.
Patients with risk factors for CHF (e.g. ischaemic or valvular disease, oedematous disorders, renal failure, COPD), reduced gastric acidity (e.g. achlorhydria), immediate life-threatening systemic fungal infections, cystic fibrosis, or immunocompromised patients (e.g. neutropenic, AIDS, organ transplant patients). Coadministration with Ca channel blockers or drugs that reduce gastric acidity. Renal and hepatic impairment. Elderly. Pregnancy (life-threatening infection) and lactation.
This drug may cause dizziness, visual disturbances and hearing loss, if affected, do not drive or operate machinery.
Monitoring Parameters Monitor LFTs, renal function tests, serum trough concentrations for other infections. Assess for signs and symptoms of heart failure.
Hypersensitivity. Non-life-threatening indications in patients with ventricular dysfunction (e.g. CHF, history of CHF). Severe renal impairment (IV). Pregnancy (non-life-threatening infection). Coadministration with astemizole, bepridil, cisapride, disopyramide, dofetilide, dronedarone, eplerenone, ergot alkaloids, felodipine, halofantrine, irinotecan, ivabradine, lercanidipine, levacetylmethadol, lovastatin, lurasidone, methadone, midazolam (oral), misolaztine, nisoldipine, pimozide, quinidine, ranolazine, sertindole, simvastatin, terfenadine, or triazolam; colchicine in patients with varying degrees of renal or hepatic impairment.
May decrease plasma concentrations with carbamazepine, phenobarbital, phenytoin isoniazid, rifabutin, rifampicin, nevirapine, efavirenz. May reduce absorption with antimuscarinics, antacids, PPIs, histamine H2-receptor antagonists. May increase plasma concentrations with indinavir, ritonavir, telaprevir, erythromycin, clarithromycin, ciprofloxacin. May reduce plasma concentration of meloxicam. May increase serum concentrations of digoxin, alfentanil, oxycodone, repaglinide, bilastine, alprazolam, midazolam (IV), buspirone, saquinavir, praziquantel, bosentan, aprepitant, reboxetine, fesoterodine, solifenacin, tamsulosin, tadalafil, sildenafil, cinacalcet, tolvaptan, antineoplastic agents (e.g. busulfan, docetaxel, trimetrexate, vinca alkaloids), immunosuppressants (e.g. ciclosporin, tacrolimus), corticosteroids (e.g. budesonide, dexamethasone, fluticasone), oral anticoagulants (e.g. apixaban, cilostazol, coumarins). May increase risk of respiratory depression with fentanyl. May enhance negative inotropic effects of verapamil.
Potentially Fatal: May increase risk of QT prolongation and ventricular tachyarrhythmia (including torsades de pointes) with astemizole, bepridil, cisapride, disopyramide, dofetilide, dronedarone, felodipine, halofantrine, lercanidipine, levacetylmethadol, mizolastine, nisoldipine, pimozide, quinidine, sertindole, and terfenadine. May increase risk of ergotism with ergot alkaloids (e.g. dihydroergotamine, ergometrine). Increased risk of myopathy including rhabdomyolysis with HMG-CoA reductase inhibitors (e.g. simvastatin, lovastatin). May potentiate hypnotic and sedative effect of triazolam and oral midazolam. May increase plasma concentrations of lurasidone, irinotecan, eplerenone, ranolazine, and colchicine (patient with renal or hepatic impairment).
Itraconazole, a triazole derivative antifungal agent, inhibits the fungal CYP450 activity, thereby decreasing ergosterol biosynthesis and inhibiting fungal cell membrane formation.